Monday, September 21, 2015

External review board rejects research proposal by Charles Schulz

Here's an interesting passage from the July 2015 minutes of the University of Minnesota IRB Executive Committee:

"The Committee reviewed a report form on Dr. Schulz’s protocol 1408M53023, “Clozapine for Cannabis Use in Schizophrenia (CLOCS)”. This study was approved by our IRB on 12/18/14, but Quorum, to whom the UMN IRB transferred oversight of this study, deemed the submitted protocol inadequate. Quorum indicated that they would not approve the study, and requested Dr. Schulz withdraw it."

This passage raises a number of questions. Why did Quorum IRB reject a protocol that the U's IRB apparently had no trouble with?  And more to the point: has this news been passed along to the state legislature along with the periodic reports that the U is legally obligated to provide?

1 comment:

  1. Here’s the official posting for the study that Charlie Schulz was going to help run:

    https://clinicaltrials.gov/ct2/show/NCT01639872

    It’s not another study focusing on first-episode psychosis as I initially thought. However, read the statement of justification and you’ll get the idea. Like monthly depot injections, clozapine is a treatment usually seen as a “last resort.” And the same crowd trying to make depot injections a first-choice treatment are also determined to expand the use of clozapine. This might not be such a good idea, to put it mildly.

    David Healy penned a good expose of clozapine’s dangers, and the campaign to promote it, a few years ago. The occasion was the TV show “Homeland Security”, in which Clare Danes plays a CIA agent whose periodic paranoid madness is supposedly held in check by taking clozapine. This may be the wildest piece of fiction in the whole improbable show, Healy says:

    http://davidhealy.org/homeland-security/

    ReplyDelete